Ramelteon attenuates age-associated hypertension and weight gain in spontaneously hypertensive rats

Annals of the New York Academy of Sciences

Volumn 1199, Issue , 2010, Pages 114-120

  Oxenkrug, Gregory F ^a   Summergrad, Paul ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Age; Age associated neuroendocrine disorders; Aging; Hypertension; Melatonin; Metabolic syndrome; Ramelteon; Spontaneously hypertensive rats; Weight gain

Indexed keywords

RAMELTEON;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD PRESSURE; BODY WEIGHT; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ACTIVITY; ESSENTIAL HYPERTENSION; FEMALE; HYPERTENSION; MALE; METABOLIC SYNDROME X; NEUROENDOCRINE DISEASE; NONHUMAN; RAT; SYSTOLIC BLOOD PRESSURE; WEIGHT GAIN;

RATTUS;

EID: 77953997242     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05355.x     Document Type: Conference Paper

References (60)

1. Jonas, M., D. Garfinkel, N. Zisapel, et al. 2003. Impaired nocturnal melatonin secretion in non-dipper hypertensive patients. Blood Press. 12: 19-24.
2. Yaprak, M. et al. 2003. Decreased nocturnal synthesis of melatonin in patients with coronary artery disease. Int. J. Cardiol. 89: 103-107.
3. Cagnacci, A. et al. 2005. Prolonged melatonin administration decreases nocturnal blood pressure in women. Am. J. Hypertens. 18(12 Pt 1): 1614-1618.
4. Kawashima, K. et al. 1984. Melatonin in serum and the pineal of spontaneously hypertensive rats.Clin. Exp. Hypertens. A 6: 1517-1528.
5. Enzminger, H. et al. 2001. Alteredmelatonin production in TGR(mREN2)27 rats: on the regulation by adrenergic agonists, antagonists and angiotensin II in cultured pinealocytes. J. Pineal. Res. 31: 256-263.
6. Oxenkrug, G.F. & P.J. Requintina. 1992. Phase advanced circadian rhythm of the pineal melatonin biosynthesis in spontaneously hypertensive rats. Biol. Psychiat. 31: 37S.
7. Oxenkrug, G.F. & P.J. Requintina. 2003. Melatonin and jet lag syndrome: experimental model and clinical implications. CNS Spectrums. 8: 139-148.
8. Oxenkrug, G.F. 1998. N-acetylserotonin and the hypotensive effect of MAO-A inhibition (mini-review). Vopr. Med. Khim. 43: 522-526.
9. Oxenkrug, G.F. 1999. Antidepressive and antihypertensive effects of MAO-A inhibition: role of Nacetylserotonin (a review). Neurobiology 792: 213-224.
10. Zanoboni, A. & W. Zanoboni-Muciaccia. 1967. Experimental hypertension in pinealectomized rats. Life Sci. 6: 2327-2331.
11. Cunnane, S.C. et al. 1980. Enhanced vascular reactivity to various vasoconstrictor agents following pinealectomy in the rat: role of melatonin. Can. J. Physiol. Pharmacol. 58: 287-293.
12. Nishiyama, K. et al. 2001. Acute effects of melatonin administration on cardiovascular autonomic regulation in healthy men. Am. Heart J. 141: E9.
13. Arangino, S. et al. 1999. Effects ofmelatonin on vascular reactivity, catecholamine levels, and blood pressure in healthy men. Am. J. Cardiol. 83: 1417-1419.
14. Lusardi, P. et al. 1997. Effect of bedtime melatonin ingestion on blood pressure of normotensive subjects. Blood Press Monit. 2: 99-103.
15. Kitajima, T. et al. 2001. The effects of oral melatonin on the autonomic function in healthy subjects. Psychiatry Clin. Neurosci. 55: 299-300.
16. Cagnacci, A. et al. 1997. Potentially beneficial cardiovascular effects of melatonin administration in women. J. Pineal. Res. 22: 16-19.
17. Cagnacci, A. 2001. Effect of exogenous melatonin on vascular reactivity and nitric oxide in postmenopausal women: role of hormone replacement therapy. Clin. Endocrinol. (Oxf.) 54: 261-266.
18. Scheer, F.A. et al. 2004. Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension 43: 192-197.
19. Grossman, E. et al. 2006.Melatonin reduces night blood pressure in patients with nocturnal hypertension. Am. J. Med. 119: 898-902.
20. Kawashima, K. et al. 1987. Antihypertensive action of melatonin in the spontaneously hypertensive rat. Clin. Exp. Hypertens. A 9: 1121-1131.
21. K-Laflamme, A. et al. 1998. Impaired basal sympathetic tone and alpha1-adrenergic responsiveness in association with the hypotensive effect of melatonin in spontaneously hypertensive rats. Am. J.Hypertens. 11: 219-229.
22. Leibowitz, A. et al. 2008. The role of melatonin in the pathogenesis of hypertension in rats with metabolic syndrome. Am. J. Hypertens. 2: 348-351.
23. Kim, C.Y. et al. 2002. Effects ofmaternal-melatonin treatment on open-field behaviors and hypertensive phenotype in spontaneously hypertensive rats' (SHR) offspring. Exp. Anim. 51: 69-74.
24. He, W. et al. 1998. Effect of melatonin on mean blood pressure and heart rate in morphine withdrawal rats. Yao Xue Xue Bao 33: 727-730.
25. Karppanen, H. 1974. Studies of pinealectomy-induced hypertension in rats. Doctoral thesis, Helsinki.
26. Oxenkrug, G.F. et al. 1986. Possible melatonin involvement in the hypotensive effect of MAO inhibitors. J. Neural Transm. 66: 271-280.
27. Oxenkrug, G.F. et al. 2000. The effect of cold immobilization stress on brainMAOAinhibitory activity and pineal N-acetyserotonin and melatonin in spontaneously hypertensive rats. Stress Med. 16: 239-241.
28. Oxenkrug, G.F. & P.J. Requintina. 1998. The effect of MAO-A inhibition and cold-immobilization stress on N-acetylserotonin and melatonin in SHR and WKY rats. J. Neural. Transm. [Suppl]. 52: 333-336.
29. Kato, K. et al. 2005. Neurochemical properties of ramelteon (TAK-375), a selectiveMT1/MT2 receptor agonist. Neuropharmacology 48: 301-310.
30. Viswanathan, M. et al. 1992. Differential expression of melatonin receptors in spontaneously hypertensive rats. Neuroendocrinology 56: 864-870.
31. Dubocovich,M.L. et al. 2003.Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front Biosci. 8: 1093-1098.
32. Ding, C.N. et al. Effects of microinjection of melatonin and its receptor antagonists into anterior hypothalamic area on blood pressure and heart rate in rats. Acta Pharmacol. Sin. 22: 997-1002.
33. Geary, G.G. et al. 1998. Effect of melatonin in the rat tail artery: role of K +channels and endothelial factors. Br. J. Pharmacol. 123: 1533-1540.
34. Masana,M.I. et al. 2002. MT(2)melatonin receptors are present and functional in rat caudal artery. J. Pharmacol. Exp. Ther. 302: 1295-1302.
35. Scheer, F.A. 2005. Potential use of melatonin as adjunct antihypertensive therapy. Am. J. Hypertens. 18(12 Pt 1): 1619-1620.
36. Hardeland, R. et al. 2008. Melatonergic drugs in clinical practice. Arzneimittelforschung 58: 1-10.
37. Johnson, M.W. et al. 2006. Ramelteon a novel hypnotic lacking abuse liability and sedative adverse effects. Arch. Gen. Psychiatry 63: 1149-1157.
38. Miyamoto, M. 2006. Effect of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist, on motor performance in mice. Neurosci. Lett. 402: 201-204.
39. Schork,N.J. et al. 1994.Relationship of growth and blood pressure in inbred rats.Am. J. Physiol. 266(3 Pt 2): R702-708.
40. Young, J.B. et al. 1978. Caloric restriction lowers blood pressure in the spontaneously hypertensive rat. Metabolism 27: 1711-1714.
41. Dilman,V.M. 1971.Age-associated elevation of hypothalamic threshold to feedback control, and its role in development, ageing, and disease. Lancet 1: 1211-1219.
42. Dilman, V.M. 1994. Development, Aging and Disease: A New Rationale for an Intervention Strategy. Harvard Acad. Publ. Zurich, Switzerland.
43. Dilman, V.M., I.P. Lapin & G.F. Oxenkrug. 1979. Serotonin and aging. In Serotonin in Health and Disease, Vol.5. W. Essman, Ed.: 111-123. Spectrum Press, NYLondon.
44. France, C.P. et al. 2006. Acute and chronic effects of ramelteon in rhesus monkeys (Macaca mulatta): dependence liability studies. Behav Neurosci. 120: 535-541.
45. Rasmussen, D.D. et al. 2001. Aging-dependent changes in the effect of daily melatonin supplementation on rat metabolic and behavioral responses. J. Pineal. Res. 31: 89-94.
46. Sanchez-Mateos, S. et al. 2007. Melatonin and estradiol effects on food intake, body weight, and leptin in ovariectomized rats. Maturitas 58: 91-101.
47. Nishida, S. et al. Long-term melatonin administration reduces hyperinsulinemia and improves the altered fattyacid compositions in type 2 diabetic rats via the restoration of Delta-5 desaturase activity. J. Pineal. Res. 32: 26-33.
48. Puchalski, S.S. et al. 2003. Melatonin effect on rat body weight regulation in response to high-fat diet at middle age. Endocrine 21: 163-167.
49. Prunet-Marcassus, B. et al. 2003. Melatonin reduces body weight gain in Sprague-Dawley rats with dietinduced obesity. Endocrinology 144: 5347-5352.
50. Henderson, D.C. 2008. Managing weight gain and metabolic issues in patients treated with atypical antipsychotics. J. Clin. Psychiatry 69: e04.
51. Raskind, M.A. et al. 2007. Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats. Neuropsychopharmacology 32: 284-288.
52. Mustonen, A.M. et al. 2001. Preliminary evidence that pharmacologic melatonin treatment decreases rat ghrelin levels. Endocrine 16: 43-46.
53. Festa, A. et al. 2000. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102: 42-47.
54. Pacifico, L. et al. 2006. Increased T-helper interferongamma-secreting cells in obese children. Eur. J. Endocrinol. 154: 691-697.
55. Oxenkrug, G.F. 2007. Genetic and hormonal regulation of the kynurenine pathway of tryptophan metabolism: new target for clinical intervention in vascular dementia, depression and aging. Ann. N.Y. Acad. Sci. 1122: 35-49.
56. Brandacher, G. et al. 2007. Chronic immune activation underliesmorbidobesity: is IDOakeyplayer? Curr.Drug Metab. 8: 289-295.
57. Brandacher, G. et al. 2006. Bariatric surgery cannot prevent tryptophan depletion due to chronic immune activation in morbidly obese patients. Obes. Surg. 16: 54154-54158.
58. Le Gouic, S. et al. 1996. Effects of both a melatonin agonist and antagonist on seasonal changes in body mass and energy intake in the garden dormouse. Int. J. Obes. Relat. Metab. Disord. 20: 661-667.
59. Walsh, H. A. & S. Daya. 1997. Inhibition of hepatic tryptophan-2,3-dioxygenase: superior potency of melatonin over serotonin. J. Pineal. Res. 23: 20-23.
60. Perianayagam, M.C. et al. 2005. Immune modulating effects of melatonin, N-acetyl serotonin and Nacetyl dopamine. Ann. N.Y. Acad. Sci. 1053: 386-393.